< Back to latest news & events

Event

WIPR webinar: Applied AI: Effectively Monetising Innovation

March 2021

Event date: 9th March 2021

WIPR and HGF are holding a webinar on 9th March.

HGF Partner Dr Susan Keston and Patent Director Dr Lauris Kemp will be presenting a webinar on 9th March on ‘Applied AI: Effectively Monetising Innovation’, where they will discuss:

  • Gain insight via examples of European patented AI innovations from life sciences and electronics
  • Understand the AI innovation landscape and its unique challenges
  • Learn how to intelligently combine patents, trade secrets and contract law to successfully monetise AI innovation

Artificial Intelligence (AI) has finally come of age and is becoming increasingly prevalent in driving revolutionary innovation across a broad range of technologies including medical diagnosis, drug discovery, image/speech processing, digital security, industrial control processes and autonomous vehicles.

Intellectual property managers are faced with unique concerns about the viability of extracting value from AI innovation via the patent system due, for example, to implementation aspects being concealed in the cloud, or due to many innovative predictions being fuelled by a unique and valuable set of training data, itself not directly protectable via the patent system, implemented on “black box” AI tools.

The speakers explore examples of granted European AI patents spanning life sciences and electronics and suggest robust monetisation strategies for AI innovation that intelligently combine patents, trade secrets, contract law and licensing.

Latest updates

The FoodTech Series #1 | Multi-parameter claims, examples outside the scope of the claims: when improvement occurs and evidence becomes easier to demonstrate

            The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they ruled on an opposition …

Read article

A New Era for AI Patents in the UK: Supreme Court Aligns with the EPO

The UK Supreme Court has handed down its long-awaited judgment in Emotional Perception AI Limited (EPAI) vs Comptroller General of Patents, a decision which serves to significantly change the way …

Read article
Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article